[PDF] Benchmarking AIDS: 2006 Year End Update

Pharmaceutical companies continue to fall short on providing access to essential medicines... However, investors found that some companies have taken steps towards improving public health in poor countries and protecting long-term shareholder value... [Includes recent steps by Abbott, Gilead, GlaxoSmithKline, Novartis, and Roche and recommendations for next steps for each of these companies.]

Chronologie

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Date:

4 Mar 2014

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Date:

30 Nov 2006

Type de contenu:

Article

Langues disponibles: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Date:

13 Sep 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Date:

13 Sep 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Date:

13 Sep 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Date:

12 Sep 2006

Type de contenu:

Article

Langues disponibles: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Date:

6 Sep 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Date:

6 Sep 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Reclaman mayor compromiso de las farmacéuticas

Date:

31 Aoû 2006

Type de contenu:

Article

Langues disponibles: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Date:

23 Aoû 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Date:

23 Aoû 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Date:

23 Aoû 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Date:

17 Aoû 2006

Type de contenu:

Article

Langues disponibles: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Date:

17 Aoû 2006

Type de contenu:

Article

Langues disponibles: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Date:

14 Aoû 2006

Type de contenu:

Article

Langues disponibles: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Date:

1 Aoû 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Date:

1 Aoû 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Date:

8 Jan 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Date:

8 Jan 2006

Type de contenu:

Réponse de l'entreprise

Langues disponibles: English

Voir l'affaire complète

Charger plus Voir moins

Business & Human Rights
Resource Centre

Centre de Ressources sur les Entreprises et les Droits de l'Homme

Cette page n’est pas disponible en Français et est affichée en English

[PDF] Benchmarking AIDS: 2006 Year End Update

Chronologie

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.